TFS HealthScience Unveils New Global Brand Identity
New identity makes clear how Swedish-founded CRO works with biotech, pharma and medtech sponsors: radical honesty, scientific urgency, therapeutic depth and teams that stay
"Our new brand shows exactly who we are and where we are going," said
Watch the TFS brand film
Watch the brand film at tfscro.com/new-brand →
The short film shows the new TFS in practice: how its teams work alongside sponsors from first patient to database lock.
What the new brand stands for
The identity anchors every study in the company's purpose: to apply a human lens to clinical development so that promising science reaches the patients who need it. TFS began in
The new brand turns that idea into four commitments sponsors can hold TFS to:
- Radical honesty. TFS teams tell sponsors exactly what the data says and flag what matters early.
- Scientific urgency. Therapeutic leads hold direct decision-making authority, so sponsors get fast decisions without escalation chains.
- Therapeutic depth. TFS focuses on five therapeutic areas: dermatology, internal medicine, neuroscience, oncology and ophthalmology. Clinical leads know the indication before kickoff.
- Teams that stay. 88% of TFS teams stay for the whole study, 8 percentage points above the industry average. The people who start a trial are still there at database lock.
Sponsors work with TFS through full delivery, embedded resourcing or a blend of both, shaped around what they keep in-house and what they hand over.
About TFS HealthScience
TFS HealthScience is a global clinical research organization (CRO) that partners with biotech, pharma and medtech sponsors to secure the path from science to life. Founded in Lund, Sweden, in 1996, TFS operates in more than 40 countries. The company focuses on five therapeutic areas: dermatology, internal medicine, neuroscience, oncology and ophthalmology. Learn more at tfscro.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tfs-healthscience-unveils-new-global-brand-identity-302915816.html
SOURCE TFS HealthScience
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MiniTool ShadowMaker 5.0 Introduces Cloud Sync for Google Drive and OneDrive
- HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial
- Puerto Rico Residents Tax-Free Fund V, Inc. Announces Path to Anticipated Expansion of Shareholder Liquidity Options
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share